PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
11 Jul, 2019 ,

The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be tolerated and result in the shrinking of cancer or stopping cancer from growing. In the phase I portion, the maximum tolerated a dose of the study drug will be determined. In the Phase II portion, progression-free survival will be assessed at the dose level found in Phase I. Participants will continue to take the study drug until they experience an unacceptable side effect or their disease progresses.